Biology of p53 protein isoforms and their significance in hematological malignancies
Clinical Scorecard: Diverse Isoforms of the p53 Protein: Implications for Hematological Cancers
At a Glance
| Category | Detail |
|---|
| Condition | Hematological Cancers |
| Key Mechanisms | p53 isoforms influence cell-cycle arrest, senescence, apoptosis, and DNA-damage responses. |
| Target Population | Patients with hematological malignancies including acute leukemias, multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphomas. |
| Care Setting | Clinical oncology and hematology. |
Key Highlights
- TP53 mutations occur in 10-30% of hematological cancer patients.
- N-terminally truncated and C-terminally spliced p53 isoforms can modulate transcriptional programs.
- 17p deletions correlate with aggressive disease and treatment resistance.
- Isoform expression can occur independently of TP53 mutation status.
- Standardized assays are needed for p53 isoform profiling in clinical settings.
Guideline-Based Recommendations
Diagnosis
- Assess TP53 mutation status and isoform expression in hematological malignancies.
Management
- Consider the role of p53 isoforms in treatment response and disease progression.
Monitoring & Follow-up
- Monitor for changes in p53 isoform expression in relapsed disease.
Risks
- Increased risk of aggressive disease and poor prognosis associated with TP53 mutations and 17p deletions.
Patient & Prescribing Data
Patients with hematological malignancies, particularly those with refractory or relapsed disease.
p53 isoforms may influence sensitivity to specific cancer treatments.
Clinical Best Practices
- Utilize standardized assays for p53 isoform detection.
- Incorporate p53 isoform profiling into risk stratification and therapeutic decision-making.
Related Resources & Content
